Anpac Bio is launching a new facility in Pennsylvania.
Anpac Bio & UCD Vet Med in Clinical Trial Studying ‘CDA’ Liquid Biopsy Tech for Canine Cancer Screening

Technical Advisory Board Member John Reddington, DVM, PhD & Biosciences Leader to Support New Anpac Bio Animal Care R&D

DAVIS, Calif., Oct. 3, 2018 — The University of California, Davis, School of Veterinary Medicine (UCDSVM) is currently conducting a formal clinical research trial studying Anpac Bio-Medical Science Company’s “Cancer Differentiation Analysis” (CDA) liquid biopsy technology’s potential application for canine cancer screening.

Respected Bioscientist and former Morris Animal Foundation CEO Dr. John Reddington, DVM, PhD, has joined the Anpac Bio-Medical Science Company Technical Advisory Board; exploring the company’s Cancer Differentiation Analysis liquid biopsy technology for potential animal disease screening. Pictured here (left-to-right): Anpac Bio Chief Financial Officer Mark Luhdorff, Chief Marketing Officer Drisha Leggitt, Technical Advisory Board Member John Reddington, and VP Technical Operations Sharon Yu.

Studying at least 186 dogs in a blinded clinical trial, Anpac Bio and the UCDSVM are investigating CDA’s ability to identify cancer in blood samples from canines confirmed with sarcomas or carcinomas versus healthy control blood samples from dogs of similar age and breed. Following the initial screening, UCDVSM will then test if CDA levels also correlate to treatment response (i.e. if the dogs’ cells are responding to cancer treatment such as surgery or radiation) and monitor remission/potential recurrence.

Anpac Bio Chief Executive Officer Dr. Chris Yu also announced this week engaging new Technical Advisory Board Member Dr. John Reddington, DVM, PhD., to help guide Anpac Bio’s research and development exploring potential animal disease screening. Recently retired as CEO of the world-renowned Morris Animal Foundation, and a highly-experienced biosciences leader at such organizations as Nova TheraNostics, Cambridge Biomedical, Sirtex Medical, and Valentis Inc., Dr. Reddington will act as Anpac Bio’s chief advisor for veterinary and comparative research.

“Dogs are just like people; the sooner we identify disease, the better chance we have in treating and curing it,” explains Reddington. “Unfortunately, dogs can’t tell us when they don’t feel well; so, we often catch diseases like cancer late stage. (Anpac Bio’s) Cancer Differentiation Analysis liquid biopsy technology has proven to be very useful in detecting over 20 human cancer types with just a single, standard blood test. If CDA technology can detect cancer in humans using just 2mL of blood, then a similar blood sample should detect canine cancer with equal effectiveness because the components in human blood and dog blood are genetically very similar. Therefore, we believe CDA technology can be extended to animals, including dogs, for cancer screening. And while the UCD Trial has just begun to test this theory, the potential of CDA liquid biopsy to support animal care seems very promising.”

The Veterinary Cancer Society reports cancer is the leading cause of death in 47% of dogs. Approximately one-in-three domestic dogs will develop cancer. And like humans, if canine cancer is diagnosed early-stage, veterinarians have many options (such as surgery, radiology, etc.), to treat and cure the disease – potentially adding years to the dogs’ life.

The Genomics Institute reports 84% of dog DNA has human counterparts and spontaneously manifests many of the same diseases like cancer. It is due to this fact – and UCDSVM’s number one world ranking; internationally renowned Comparative Cancer Center; and close geographic location to Anpac Bio’s Sacramento, California headquarters – that the company approached UCD’s veterinary researchers to independently test/study if CDA liquid biopsy technology can detect animal cancer, as it does in humans.

Since 2008, Anpac Bio pioneered liquid biopsy research for human cancer screening. Comprehensive research validity data from 100,000+ human cases processed (to date) demonstrate CDA diagnostics consistently detects 26+ different cancers — with sensitivity and specificity rates of 75%-90% — usually identifying the disease at the earliest stages. And it does so without any harmful side effects in patients, generating far fewer “false positives”, at a cost substantially lower than traditional testing (such as imaging), and generating results within minutes of sample submission.  Anpac Bio has filed 250+ CDA-related patent applications worldwide – 101+ issued by 20 countries (to date) and is fully-commercialized and earning liquid-biopsy screening revenue.

“Anpac Bio is very proud to be working with such an esteemed and experienced biosciences and veterinary researcher as Dr. Reddington,” states Yu. “And we are excited that UCD is conducting a full clinical research trial testing CDA’s potential applications for canine cancer screening. Since we launched our company and pioneered liquid biopsy technology, we have identified cancer in thousands of people – saving lives every day. As the majority of our Anpac Bio employees are also animal lovers, we are thrilled that CDA may also help the veterinary community catch canine cancer – and perhaps other animals – as effectively as it has in humans. We look forward to one day supporting medical professionals worldwide catch and cure cancers in all of our loved ones – whether they walk on two legs or four!”